Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 2010

View Archived Issues

NicOx's NO-donating agents show preclinical promise in ophthalmology and pain

Serum bilirubin modulates response to bucindolol in patients with heart failure

Potent inhibitors identified of GIST-relevant kinases

Merck & Co. claims new cholesterol absorption inhibitors

Merck & Co. presents new sst5 receptor antagonists

NeuroSearch discovers new monoamine reuptake inhibitors

GlaxoSmithKline presents new AMPA receptor agonists

TransTech and Forest enter into agreement to develop GKAs

Vivalis and Sanofi Pasteur join to discover MAbs for infectious diseases

Nautilus Neurosciences launches Cambia for migraine in the U.S.

Simvastatin/ezetimibe combination promotes tumor growth in prostate cancer model

QBI-139 enters phase I trial in advanced/refractory solid tumors

Inhaled formoterol fumarate/glycopyrrolate is safe in healthy subjects

Protalix BioTherapeutics completes phase I trial of PRX-105

European Commission extends indication of RoActemra

Phase II data reported on IFN alpha-2b in patients with anogenital warts

Discovery receives FDA guidance for preclinical Surfaxin program in neonatal RDS

Idera reports preliminary phase I data on IMO-3100

Nektar Therapeutics reports phase II data on NKTR-102 in breast cancer

Aerovance presents phase IIb data on pitrakinra in eosinophilic asthma

NanoViricides' anti-HIV candidates efficacious against two HIV-1 isolates in vitro

Columbia Labs completes enrollment in phase III Prochieve trial

Eisai and Helsinn enter license agreement for antiemetic combination agent

Engrailed-2 proposed as diagnostic biomarker for prostate cancer

Phase III lubiprostone trial in idiopathic constipation complete

Eisai presents the year's product and financial highlights

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...